6c3fd2dd__Trials_Monthly___October_2013__Description
[NCI Designation] NCT01922921 [Disease Site] Breast Cancer [Description] 
Phase I/II Randomized Study of Combination Immunotherapy with or without Polysaccharide Krestin (PSK®) Concurrently with a HER2 ICD Peptide-Based Vaccine and Trastuzumab in Patients with Stage IV Breast Cancer
Seattle Cancer Care Alliance | Clinical Trials Monthly - October 2013
Description